Compare Crispr Therapeutics AG (CRSP) vs Western Digital Corp (WDC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Western Digital Corp — how do they compare? Crispr Therapeutics AG trades at $53.98 (market cap $5.23B), while Western Digital Corp trades at $461 (market cap $150.95B). The key difference: Western Digital Corp is far larger — about 28.9× Crispr Therapeutics AG's market cap, and Western Digital Corp pays a 0.14% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| CRSP | WDC | |
|---|---|---|
Market Cap | $5.23B | $150.95B |
Sector | Health | Technology |
52-Week High | $76.78 | $746.23 |
52-Week Low | $44.34 | $74.66 |
Enterprise Value | $3.65B | $150.42B |
Dividend Yield | — | 0.14% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $53.83, up 0.6% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a Q2 2026 EPS beat with a loss of $0.94 versus an expected $1.19 loss, driven by surging CASGEVY sales. However, financials show deep losses, with a net income margin of -4,101.26% in 2025 and negative operating cash flow, though financing activities provided liquidity.
The outlook is mixed: strong analyst consensus (57.9% buy ratings) and a $82.67 price target reflect optimism around CASGEVY growth and pipeline catalysts, but high valuation (P/S of 466.05) and persistent cash burn pose significant risks. Investment appeal hinges on successful clinical advancements and path to profitability.
Western Digital (WDC) trades at $454.34, up 3.7% in the last 24 hours, with strong earnings beats in recent quarters and a bullish analyst consensus of 72% buy ratings. The stock faces bearish technical signals but benefits from robust AI-driven storage demand, evidenced by 44% revenue growth in Q4 2026 and a net income margin of 72.95% in 2025. Recent news highlights its positioning as a key player in AI infrastructure, though valuation concerns persist.
The outlook for WDC is positive due to sustained AI storage demand and margin expansion, but risks include high valuation multiples and cyclical industry pressures. With a consensus price target of $665.15, upside potential exists, yet investors should monitor competitive threats and earnings sustainability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Western Digital Corp
Western Digital is a vertically integrated supplier of data storage solutions, spanning both hard disk drives and solid-state drives. In the HDD market it forms a practical duopoly with Seagate, and it is the largest global producer of NAND flash chips for SSDs in a joint venture with competitor Kioxia.
Read more on WDC →
